Introduction
Non‑surgical cosmetic injectables in Ireland, primarily botulinum toxin (“Botox”) and dermal fillers, operate within a fragmented regulatory framework. Botox is a tightly controlled, prescription-only medicine and may only be prescribed and administered by authorised healthcare professionals in accordance with Irish law. Dermal fillers, however, are regulated at EU level as high-risk medical devices; they are subject to a detailed product regulatory regime which governs product safety and market placement, but does not restrict who may administer them.
Despite the level of regulation applied to these products, Ireland has not introduced a licensing regime for aesthetic practitioners or premises. The result is a regulatory asymmetry: non-medical practitioners may lawfully inject CE-marked fillers, yet cannot lawfully prescribe, supply or administer Botox. Professional standards apply only to regulated clinicians, leaving unregistered providers outside formal clinical oversight. This divergence creates practical uncertainty for clinicians and ongoing concerns around patient safety, quality of care and legal exposure.
Botox
Under Irish medicines legislation, Botox is classified as a prescription-only medicine and may only be prescribed and administered by doctors, dentists, or nurses acting under appropriate clinical direction. Any supply or administration outside these parameters is unlawful.
In recent years, the Health Products Regulatory Authority (‘HPRA’) has increased its enforcement activity by over 400%. Large quantities of unauthorised products have been seized, investigations into improper supply chains are ongoing, and numerous online posts have been removed for unlawfully promoting prescription-only medicines to the public. These actions signal a clear regulatory focus on curbing unlawful practice in the aesthetics sector and serve as a reminder that breaches of medicines legislation may expose providers not only to regulatory action, but also to criminal sanctions including prosecution, fines and, in serious cases, imprisonment.
In the clinical setting, statutory requirements operate alongside professional obligations. Prescribers are expected to conduct an in-person consultation, obtain informed consent, document the clinical indications and ensure that appropriate emergency resources are available. While legislation sets the legal baseline, it is professional guidance that largely defines what constitutes safe, defensible and ethically compliant aesthetic practice.
Dermal fillers
Dermal fillers used for cosmetic purposes fall within Annex XVI of the EU Medical Device Regulation (MDR 2017/745). This brings products with a non-medical purpose, but comparable risk profile, within a structured device safety regime.
The following dermal filler brands appear to be widely used in Irish clinics and are CE-‑marked under the EU Medical Device Regulation (MDR 2017/745):
- Hyaluronic Acid (HA) Fillers: Juvederm® (Allergan), Restylane® (Galderma), Teoxane / Teosyal®, Belotero®, Saypha®, Stylage® (Vivacy)
- Non-‑HA or Specialised Fillers: Sculptra® (poly-‑L-‑lactic acid) and Radiesse® (calcium hydroxylapatite)
Only CE-‑marked fillers compliant with MDR 2017/745 should be used in Ireland.
The introduction of Common Specifications in late 2022 strengthened these obligations. Manufacturers must now maintain comprehensive risk management systems, undertake appropriate clinical evaluations, implement enhanced labelling and traceability requirements, and engage in post market surveillance. CE-marking through a Notified Body is mandatory, and fillers are generally treated‑ as Class III devices.
For practitioners in Ireland, the implications are relatively clear; only CE-marked fillers compliant with these MDR requirements should be used, and clinics must ensure proper procurement and maintain adequate records. However, while the MDR governs how fillers are classified and placed on the market, it does not regulate who may inject them or the standards of the clinical environment in which they are administered. Those questions are left to EU Member States, and in Ireland a regulatory gap remains.
Professional regulatory standards
In the absence of dedicated legislation, Ireland continues to rely on professional regulators to set standards for registered practitioners providing aesthetics procedures. The Medical Council’s 2024 Guide places clear obligations on doctors in relation to competence, consent, patient safety and responsible communication. The Dental Council requires dentists who perform cosmetic injections to be appropriately trained, to use authorised or CE-marked products, and to obtain informed consent.
Similarly, the Nursing and Midwifery Board of Ireland (‘NMBI’) also provides guidance for nurses undertaking aesthetic procedures, emphasising scope of practice, documentation, clinical governance and adherence to medicines legislation, particularly where prescription-only medicines are involved.
However, these professional frameworks only apply to regulated professionals. Individuals who are not subject to statutory professional regulation fall entirely outside their scope. The result is an uneven regulatory landscape, in which the standards of practice, accountability and governance depend on whether the provider is professionally registered, rather than on the nature or risk of the procedure being performed.
Advertising and promotion
Irish law prohibits the public advertising of prescription-only medicines, and the HPRA has issued detailed guidance on how providers must comply with these restrictions. In parallel, the Advertising Standards Authority for Ireland (‘ASAI’) applies its advertising codes, which require that any health-related claims be evidence-based, responsible and not misleading.
Enforcement in this area has been particularly visible online, where both direct and indirect references to Botox are routinely removed. Providers are therefore expected to keep their public communications – including websites and social media - under active review, ensuring ongoing compliance and avoiding any trivialisation of the risks associated with aesthetic procedures.
Consumer protection obligations
Cosmetic procedures are also considered consumer services for the purposes of the Consumer Rights Act 2022. Providers must deliver services with reasonable care and skill, adopt fair and transparent contractual terms, and avoid misleading or aggressive commercial practices. Oversight by the Competition and Consumer Protection Commission (‘CCPC’) reinforce these obligations, which apply regardless of whether the provider is a regulated health professional or an unregulated practitioner, creating potential liability exposure irrespective of professional status.
Regulatory concerns
Ireland has not yet introduced a statutory licensing regime for aesthetic practitioners or premises. As a result, non-medical practitioners may lawfully administer CE-marked dermal fillers in Ireland, notwithstanding their classification as high-risk medical devices, while botulinum toxin remains strictly controlled under medicines law.
The absence of a statutory framework governing training requirements, premises standards, emergency response capacity, or clinical governance for filler procedures represents a significant regulatory gap. Government proposals to progress the Patient Safety (Licensing) Bill suggests movement toward broader licensing and oversight, which may, in time, extend to cosmetic practice.
Practical implications
For clinicians, compliance with medicines law is fundamental. Safe practice also requires an appropriate clinical environment, adherence to professional guidance and careful governance of advertising and public communications.
For non-medical providers, lawful activity is limited to ‘device-based’ procedures. This carries obligations to ensure legitimate sourcing and use of CE-marked fillers, to maintain clear protocols for managing complications and to comply fully with consumer protection law. Any involvement in the supply or administration of Botox outside a proper lawful prescription pathway carries clear legal and regulatory risk.
Conclusion
Ireland’s regulatory framework for aesthetic injectables is robust in its treatment of medicines, medical devices, and professional conduct, but remains incomplete in relation to practitioner licensing and premises standards. Until dedicated legislation is introduced, the most defensible approach for all providers (particularly those outside statutory professional regulation), is to adopt governance standards equivalent to those expected of regulated healthcare professionals. This offers the greatest protection for patients and reduces legal and reputational exposure.
Key takeaways
- Botox is a prescription-‑only medicine in Ireland and may only be prescribed and administered by authorised health professionals. Any other use is unlawful.
- Dermal fillers are Class III medical devices under the EU MDR and must be CE-‑marked and compliant with strict safety and labelling requirements.
- Ireland has no statutory licensing regime for aesthetic practitioners or premises. Non-‑medical injectors may therefore legally administer CE-‑marked fillers but cannot lawfully supply or inject Botox.
- Professional guidance applies only to regulated clinicians (doctors, dentists, nurses), leaving unregistered providers outside formal oversight.
- Advertising restrictions are strict: public promotion of prescription-‑only medicines, including direct or indirect references to Botox, is prohibited.
- Consumer protection law applies to all providers, regulated or not, including duties around obligations relating to fair contractual terms, service quality, and non ‑misleading commercial practices.
- To minimise legal, regulatory and reputational risk, providers should adopt healthcare ‑grade governance, including robust consent, documentation, emergency planning and appropriate product procurement.
Need tailored advice or guidance?
For queries on compliance, regulatory obligations, or risk management in aesthetic practice, please get in touch with the authors or other experts from our Healthcare Team.
